Clinical Trials Browser

NCT02359565 2026-03-18

Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma

Familial ependymoma, Turcot syndrome, Diffuse Intrinsic Pontine Glioma, Brain Neoplasms, Colorectal Neoplasms, Hereditary Nonpolyposis, Ependymoma, Glioma, Medulloblastoma

NCT06556563 2026-03-13

EF-41

Phase 3 Recruiting

741 enrolled

CNS

Glioblastoma

NCT02287428 2026-03-12

Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM

Phase 1 Recruiting

56 enrolled

CNS

Glioblastoma

NCT02896335 2026-03-12

Palbociclib and Pembrolizumab In Central Nervous System Metastases

Phase 2 Recruiting

45 enrolled

CNS

Brain Neoplasms

NCT05484622 2026-03-12

Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma

Phase 1 Active not recruiting

60 enrolled

CNS

Astrocytoma, Oligodendroglioma

NCT02858869 2026-03-09

Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases

Phase 1 Completed

25 enrolled 14 charts

CNSDermatologicThoracic

Uveal Melanoma, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT05188508 2026-03-06

Pembrolizumab, Olaparib, and Temozolomide for People With Glioma

Phase 2 Recruiting

57 enrolled

CNS

Glioma

NCT05463848 2026-03-04

Surgical Pembro +/- Olaparib w TMZ for rGBM

Phase 2 Recruiting

78 enrolled

CNS

Glioblastoma

NCT02658279 2026-03-03

Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype

Phase NA Active not recruiting

27 enrolled

CNS

Glioma

NCT06047379 2026-03-02

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Phase 1/2 Recruiting

134 enrolled

CNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Astrocytoma, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Central Nervous System Neoplasms, Small Cell Lung Carcinoma

NCT07410676 2026-02-18

EBNK-ST-001

Phase 1/2 Recruiting

83 enrolled

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicOther hematologic neoplasmSarcomaThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Bronchogenic, Disease, Esophageal Neoplasms, Glioblastoma, Kidney Neoplasms, Leukemia, Liver Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms

NCT04348747 2026-02-12

Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer

Phase 2 Recruiting

23 enrolled

BreastCNS

Brain Neoplasms, Triple Negative Breast Neoplasms

NCT03405792 2026-02-06

2-THE-TOP

Phase 2 Active not recruiting

40 enrolled 11 charts

CNS

Glioblastoma

NCT07385846 2026-02-04

Pilot Study of Navigated Focused Ultrasound and Pembrolizumab in the Treatment of Recurrent WHO Grade 4 IDH-Wildtype Glioblastoma With Mismatch Repair Deficiency

Phase 1 Not yet recruiting

8 enrolled

CNS

Turcot syndrome, Glioblastoma

NCT07301268 2026-02-03

GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma

Phase 2 Suspended

36 enrolled

CNSSarcoma

Astrocytoma, Glioblastoma, Gliosarcoma

NCT07347210 2026-01-16

MATVAC-1

Phase 2 Not yet recruiting

98 enrolled

CNS

Primary Glioblastoma

NCT05465954 2026-01-12

Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma

Phase 2 Recruiting

54 enrolled

CNSSarcoma

Glioblastoma, Gliosarcoma

NCT03873818 2026-01-09

Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain

Phase 2 Completed

24 enrolled 13 charts

CNSDermatologic

Brain Neoplasms, Melanoma

NCT03277638 2026-01-08

Laser Interstitial Thermotherapy (LITT) Combined With Checkpoint Inhibitor for Recurrent GBM (RGBM)

Phase 1/2 Active not recruiting

32 enrolled

CNS

Brain Neoplasms, Glioblastoma

NCT06558214 2026-01-07

OPTIMUS PRIME

Phase 2 Recruiting

20 enrolled

CNS

Glioblastoma

NCT06514898 2025-12-18

MATCHPOINT

Phase 1 Active not recruiting

12 enrolled

CNS

Medulloblastoma

NCT05317858 2025-12-10

LIMITLESS

Phase 3 Recruiting

30 enrolled

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT04955743 2025-11-24

Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma

Phase 2 Terminated

18 enrolled

CNSDermatologicGenitourinary

Brain Neoplasms, Carcinoma, Renal Cell, Melanoma

NCT04483778 2025-11-20

B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults

Phase 1 Active not recruiting

68 enrolled

CNSDermatologicGastrointestinalGenitourinaryOther solid neoplasmSarcoma

Carcinoma, Melanoma, Neoplasms, Germ Cell and Embryonal, Wilms Tumor, Neuroblastoma, Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Sarcoma, Synovial, Hepatoblastoma, Sarcoma, Clear Cell, Neurofibrosarcoma, Rhabdoid Tumor, Desmoplastic Small Round Cell Tumor

NCT04964960 2025-10-31